Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
Ras inhibitors and related small GTPase modulators act on KRAS and on the Rac, Rho and Cdc42 proteins. Small GTPases of the Ras superfamily work as molecular switches. They cycle between an active form bound to guanosine triphosphate (GTP) and an inactive form bound to guanosine diphosphate (GDP). Oncogenic KRAS mutations such as G12C keep the protein in its signaling state. ARS-853 and KRas G12C inhibitor 4 target the mutant cysteine of KRAS G12C, while Kobe2602 interferes with binding of Ras to Raf. Salirasib, a farnesylcysteine mimetic, disrupts the membrane association of Ras. Rho-family tools include NSC 23766 and EHT 1864, which inhibit Rac, and CASIN, which targets Cdc42.
KS-58 is a K-Ras (G12D) inhibitory peptide that selectively targets and binds to K-Ras. It effectively enters cells to disrupt intracellular interactions between Ras and effector proteins. This compound demonstrates significant antitumor activity by inhibiting the proliferation of tumor cells, making it a valuable tool for research on K-Ras-related cancers and therapeutic interventions.
Out of stock
All 3 sizes
KRAS-IN-5 is a selective inhibitor targeting KRAS mutants, including KRASG12D and KRASG12V, with a GNE IC50 value of 1.3 nM against KRASG12D. This compound inhibits KRAS-mediated signaling pathways, effectively blocking tumor cell proliferation by reducing ERK phosphorylation. KRAS-IN-5 exhibits potential for research applications in KRAS mutation-related cancers, including pancreatic, colorectal, and lung cancer.
Out of stock
All 3 sizes
KRAS G12C inhibitor 20 is a selective inhibitor targeting the KRAS G12C mutation. This compound exhibits significant anticancer activity by disrupting KRAS signaling pathways, thereby inhibiting cellular proliferation in KRAS-dependent tumors. It is applicable in research focused on cancer biology and targeted therapies for malignancies associated with the KRAS G12C mutation.
KRAS inhibitor-26 is a potent inhibitor targeting the KRAS G12V mutation, exhibiting an IC50 of ≤100 nM. This compound effectively disrupts oncogenic signaling pathways associated with KRAS, making it a valuable tool for cancer research. Its applications include studies on tumor growth, survival, and potential therapeutic interventions in KRAS-driven malignancies.
Out of stock
All 3 sizes
ZINC09659342 is an inhibitor of the Lbc-RhoA interaction, exhibiting an IC50 value of 3.6 μM. This compound serves as a valuable tool for studying RhoA-mediated cellular processes and signaling pathways. Its ability to disrupt Lbc-RhoA interactions makes it suitable for research applications in cancer biology and cellular mechanism studies.
KRAS Inhibitor-25 is a pyridopyrimidine compound that selectively inhibits KRAS with an IC50 of less than 100 nM for KRas G12V, KRas wild type (WT), and KRas G12R variants. This inhibitor is valuable for research applications focused on understanding KRAS-driven oncogenic signaling pathways and developing targeted cancer therapies. Its potency makes it suitable for studies investigating the biological effects of KRAS mutations and their role in tumorigenesis.
LZTR1-KRAS modulator 1 is designed to modulate the interaction between KRAS and LZTR1, thereby enhancing the recruitment of the LZTR1-KRAS complex. This compound is crucial for studies investigating the regulation of KRAS signaling pathways and their implications in cellular processes. Its application can further elucidate the role of LZTR1 in cancer biology and potential therapeutic interventions targeting KRAS-driven tumors.
Synonyms: 8-(4-Hydroxyphenylthio)-2'-O-Me-cAMP
8-pHPT-2'-O-Me-cAMP is a cAMP analog that acts as an Epac agonist, specifically enhancing the activity of the exchange protein activated by cyclic AMP (Epac). This compound is utilized in cardiac research to explore signaling mechanisms and cellular responses associated with cardiac function and pathophysiology. Its ability to modulate Epac pathways makes it a valuable tool for investigating the roles of cAMP in cardiac health and disease.
KRAS G12C Inhibitor 62 is designed to selectively inhibit the KRAS G12C mutant protein. This compound demonstrates potential in the study of KRAS G12C-mediated cancers, offering valuable insights into therapeutic strategies targeting this challenging oncogenic driver. Its application may facilitate research into tumor growth inhibition and the underlying mechanisms of KRAS-related malignancies.
Out of stock
All 3 sizes
RasGRP3 ligand 1 is a specific ligand for RasGRP3 with a binding affinity characterized by a Ki of 1.75 nM. This compound effectively induces Ras activation, making it a valuable tool for investigating downstream signaling pathways in cancer research. Its targeted mechanism allows for detailed studies of RasGRP3's role in cellular processes associated with tumorigenesis.
Z52/Z56 intermediate is a crucial building block in the synthesis of RAS inhibitors. This compound plays an important role in facilitating research on the modulation of RAS signaling pathways, which are critical in cancer biology. Its use in the development of RAS-targeted therapeutics makes it valuable for studies focused on oncogenic signaling and drug discovery efforts in oncology.
Out of stock
All 3 sizes
L 731734 is a prodrug of L-731735, designed to inhibit Ras processing in v-ras-transformed cells. This compound plays a critical role in the study of cell signaling and oncogenic processes associated with Ras. Its application in research provides valuable insights into targeted cancer therapies and the manipulation of Ras signaling pathways.
L-739749 is a potent farnesyltransferase inhibitor that selectively inhibits the prenylation of Ras proteins. This compound has demonstrated significant efficacy in blocking the hypersensitivity of juvenile myelomonocytic leukaemia (JMML) cells to granulocyte-macrophage colony-stimulating factor (GM-CSF). In vitro studies show that L-739749 effectively reduces the growth of primary human JMML cells, making it a valuable tool for research into targeted therapies for this disease.
Out of stock
All 3 sizes
(+)-Oxanthromicin is a K-Ras localization modulator that disrupts the localization of oncogenic mutant K-Ras from the plasma membrane in intact Madin-Darby canine kidney (MDCK) cells. This compound demonstrates significant antitumor efficacy, making it valuable for research into cancer biology and potential therapeutic strategies targeting K-Ras-mediated signaling pathways. Its ability to alter K-Ras localization positions it as a promising candidate in the development of targeted cancer therapies.
Dykellic acid is a potent inhibitor of RhoA, a small GTPase involved in regulating cell migration and cytoskeletal dynamics. This compound demonstrates significant inhibitory effects on the migration and motility of B16 melanoma cells, as well as on the tube formation capacity of human umbilical vein endothelial cells (HUVECs). Dykellic acid holds promise for applications in cancer research, particularly related to metastatic processes and tumor microenvironment interactions.
Out of stock
All 3 sizes
SML-10-70-1 is a K-Ras ligand that covalently modifies the K-Ras G12C mutant protein, providing a targeted approach in cancer research. This compound effectively inhibits the phosphorylation of ERK and Akt, key signaling pathways involved in cell proliferation. In vitro studies demonstrate that SML-10-70-1 significantly reduces the proliferation of cancer cell lines H23, H358, and A549, with IC50 values ranging from 26.6 to 47.6 μM, indicating its potential utility in therapeutic applications against K-Ras-driven malignancies.
pan-KRAS ligand 1 is a potent ligand designed for Target Protein applications within PROTAC technology. It facilitates the development of PROTAC pan-KRAS degrader 4, enabling targeted degradation of KRAS mutants. This compound is instrumental for researchers investigating KRAS-related oncogenic pathways and therapeutic strategies against cancer.
Out of stock
All 3 sizes
Sp-8-Br-2'-O-Me-cAMPS is a cAMP analog that serves as a potent activator of the exchange protein directly activated by cyclic AMP (EPAC). This compound is valuable for studying the role of EPAC in various biological pathways, particularly those related to metabolism. Its ability to modulate EPAC activity makes it an important tool for investigating signaling mechanisms and their implications in metabolic processes.
Synonyms: 6-Thioguanosine 5'-diphosphate
6-T-GDP (6-Thioguanosine 5'-diphosphate) operates as a metabolite of azathioprine, targeted for its role in modulating inflammatory responses. By inhibiting Rac1 activity, 6-T-GDP reduces the transcription of inflammatory factors and decreases the expression of cell adhesion molecules. This action subsequently inhibits leukocyte migration and the onset of tissue inflammation, making it a valuable reagent for research into inflammatory diseases and mechanisms of immune regulation.
Synonyms: 2'-O-Methyladenosine-3',5'-cyclic monophosphate
2'-O-Me-cAMP is a cAMP analogue that selectively stimulates exchange proteins activated by cAMP (Epac). This compound serves as a valuable tool for studying cAMP-mediated signaling pathways and the role of Epac in various biological processes. Its low membrane permeability can provide insights into the mechanisms of cAMP action in cellular contexts.
Out of stock
All 3 sizes
SCH-53870 is a Ras activation inhibitor that specifically binds to the Ras-GDP complex, thereby maintaining Ras in an inactive GDP-bound state and inhibiting its activation to the GTP-bound form. This compound modulates cell signaling pathways and subsequently affects cell proliferation by obstructing Ras activation. SCH-53870 is applicable in cancer research, providing a valuable tool for studying Ras-related oncogenic mechanisms.
NY-0173 is an antagonist of exchange proteins directly activated by cAMP (EPAC), demonstrating IC50 values of 3.5 μM for EPAC2 and 4.0 μM for EPAC1. This reagent serves as a valuable tool for investigating the biological roles and pathways mediated by EPAC. Researchers can utilize NY-0173 to explore its impact on cellular processes influenced by EPAC signaling.
ARN25062 is a potent inhibitor targeting CDC42 and RHOJ, demonstrating significant antitumor activity. This novel trisubstituted pyrimidine derivative is suitable for research applications investigating the modulation of cell signaling pathways involved in cancer progression and metastasis. Its specific inhibition of CDC42 and RHOJ makes it a valuable tool for studying cellular processes related to tumorigenesis.
Goralatide is a Ra activator that modulates the thermal sensitivity of hematopoietic progenitor cells. It enhances the disparity in thermal sensitivity between leukemia progenitor cells and normal hematopoietic progenitor cells, thereby increasing the efficacy of hyperthermia therapy. This compound is relevant for research in cancer treatment strategies, particularly those involving targeted thermal therapies.
Sp-8-pCPT-2'-O-Me-cAMPS is a selective activator of the exchange protein directly activated by cyclic AMP (EPAC). This compound enhances EPAC-mediated signaling pathways, playing a significant role in the regulation of various physiological processes. It is valuable for research into endocrine metabolism and related signaling mechanisms.
Out of stock
All 3 sizes